Status:
COMPLETED
A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing sym...
Eligibility Criteria
Inclusion
- Persisting symptoms of GORD despite previous treatment with a full dose proton pump inhibitor
- informed consent
- over 18 years of age
Exclusion
- Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to enrolment in the study
- More than 1 other course of PPI treatment in the previous 12 month
- previous use of esomeprazole
- presence of alarm symptoms
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
314 Patients enrolled
Trial Details
Trial ID
NCT00734097
Start Date
November 1 2007
End Date
October 1 2008
Last Update
October 10 2012
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Buenos Aires, Argentina
2
Research Site
Santiago, Chile
3
Research Site
Temuco, Chile
4
Research Site
Viña del Mar, Chile